Brianne Jahn
Corporate Officer/Principal en LIANBIO .
Fortuna: 73 597 $ al 31/05/2024
Perfil
Brianne Jahn's current job(s) include being the Chief Business Officer at LianBio and a Member-Supervisory Board at Shanghai Lianbio Development Co., Ltd.
Mr. Jahn's former job was as the Senior VP-Finance & Strategic Operations at Kadmon Holdings, Inc. from 2012 to 2020.
Mr. Jahn's education history includes an MBA from New York University and an undergraduate degree from the University of Massachusetts.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
LIANBIO
0.21% | 29/03/2023 | 224 005 ( 0.21% ) | 73 597 $ | 31/05/2024 |
Cargos activos de Brianne Jahn
Empresas | Cargo | Inicio |
---|---|---|
LIANBIO | Corporate Officer/Principal | 01/09/2021 |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Brianne Jahn.
Empresas | Cargo | Fin |
---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 01/01/2020 |
Formación de Brianne Jahn.
University of Massachusetts | Undergraduate Degree |
New York University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
LIANBIO | Health Technology |
Empresas privadas | 2 |
---|---|
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Brianne Jahn